NCIt definition : An immunotherapeutic consisting of the recombinant fusion protein WT1-A10 combined
with the adjuvant ASO1B with potential immunostimulating and antineoplastic activities.
Upon administration, WT1-A10/AS01B immunotherapeutic GSK2130579AWT1 may induce a WT1-specific
cytotoxic T-lymphocyte (CTL) response against WT1-expressing tumor cells, resulting
in cell lysis and the inhibition of cellular proliferation. The tumor-associated antigen
WT1 (Wilms tumor protein-1) is overexpressed in most types of leukemia and in a variety
of solid cancers. WT1-A10 is a 292 amino acid recombinant fusion protein consisting
of a 12-mer truncated tat sequence (leader sequence) and amino acids number 2-281
of the WT1 sequence; ASO1B consists of a combination of the adjuvants monophosporyl
lipd A (MPL) and Q21.;
Semantic type(s)